18hon MSNOpinion
Claude joins the ward as Anthropic eyes US healthcare data
In a blog post over the weekend, Anthropic trumpeted the launch of Claude for Healthcare alongside expanded life sciences ...
Eisai And Nuvation Bio Enter Into Exclusive Licensing Agreement For Taletrectinib In Europe And Additional Countries Outside The U.S., China And Japan. Eisai and Nuvation Bio Enter into Exclusive ...
Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany? 12 January, 2026 ? Boehringer Ingelheim today announced a strategic ...
Strategic collaboration expands taletrectinib global reach with a leading oncology partnerEisai will receive exclusive development, registration and commercialization rights for taletrectinib for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results